EirGenix Inc (台康生技) plans to transfer its listing from the Emerging Stock Board to the Taipei Exchange (TPEX) by the end of next month, chief finance officer Cathy Yang (楊秀權) told a news conference in Taipei yesterday.
The pharmaceutical company, which is a contract development and manufacturing organization (CDMO) and biosimilars maker, started trading its shares on the Emerging Stock Board in November 2016.
It aims to raise NT$600 million (US$19.06 million) through the TPEX debut and would use the proceeds for new drug studies and tests, Yang said.
EirGenix plans to issue 20 million new shares, with the listing price likely set at NT$32, but the final price would depend on the average price on the Emerging Stock Board 30 days before the TPEX listing, Yang added.
It submitted its applications to TPEX in December last year and received approval in March, even though it has yet to turn a profit.
A 2017 recommendation letter from the Industrial Development Bureau (IDB) allowed it to circumvent some listing requirements regarding revenue, earnings and cash flow, the company said.
EirGenix reported net losses of NT$368 million for last year, compared with net losses of NT$175 million in 2017, company data showed.
It plans to spend part of money from the TPEX listing for the phase III clinical trials for its breast cancer drug EG12014, chief executive officer Liu Lee-cheng (劉理成) said.
The drug is a biosimilar of trastuzumab, a monoclonal antibody sold by Swiss pharmaceutical giant Roche Holding AG under the brand name Herceptin, Liu said.
The business potential for EG12014 is huge, as its price would be cheaper than Herceptin, he said, adding that Herceptin’s annual sales last year were 6.98 billion Swiss francs (US$6.94 billion at the current exchange rate).
Herceptin’s patent for Europe expired in 2014, and that for the US is due to expire later this year, which means EG12014 has great potential, he said.
EirGenix has gained regulatory approvals to launch the phase III trials in Taiwan, the US, Georgia, Russia, India and South Korea, and has been meeting with the EU regulator to discuss the trials, Liu said.
“We will invite 800 breast cancer patients to take part in the global clinical trials, and have enrolled 66 so far,” Liu said.
The final-stage trial is expected to be completed in the fourth quarter of next year, or the first quarter in 2021, and the company should gain marketing approvals in 2021 or 2022, he said.
EirGenix last month secured a contract with Sandoz AG to provide the EG12014 for the generic pharmaceuticals division of Swiss giant Novartis AG, Liu said.
The deal would generate US$70 million over next few years, including a US$5 million upfront payment and US$65 million milestone payment, he said.
The headline has been corrected since it was first published.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by